Web version

The value of molecular imaging for prostate cancer

Molecular imaging without compromise

1 in 7 men will be diagnosed with prostate cancer during their lifetime.¹ 1.1 million are diagnosed annually worldwide.² 20-30% of all patients relapse after five years.¹


Molecular imaging plays an important role in the evaluation of prostate cancer and visualizes the extent of disease and biological response to treatment throughout the continuum of care.


Although the present application of new tracers in molecular imaging is used to help determine recurrence, evaluation of primary disease and theranostics are emerging topics of investigation.


Learn more about our comprehensive solutions in prostate cancer.

Read more

Stay up-to-date with the Siemens Healthineers Newsletter.
Sign up today for the latest news, education, and offers.
Contact Us | Privacy Policy
1 Data courtesy of http://seer.cancer.gov/statfacts/html/prost.html and http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence
2 Torre, LA., et al. Global cancer statistics, 2012, CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262.
Image data courtesy Praxis für Fusionierte Bildgebung, Halle (Saale), Germany.
This email was sent by:
Siemens Healthcare GmbH | Henkestr. 127, 91052 Erlangen, Germany
Information for healthcare professionals. The Siemens Healthineers newsletter and websites, including but not limited to siemens.com/healthineers and its affiliated sites, provide an online resource for healthcare professionals
 Do not reply to this email as it was sent from an unmonitored account.
Unsubscribe from the Molecular Imaging Insider.
Reset your password.
Contact AuntMinnie.com support.
AuntMinnie.com Privacy Policy
Email sent to: .

AuntMinnie.com, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA - (520) 298-1000